In short
BT-001 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article explores the ongoing research on BT-001, its potential benefits, and its use in combination with pembrolizumab for treating various types of cancer, including soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple-negative breast cancer, and non-small cell lung cancer.
At a glance
- Drug Name
- BT-001 (TG6030)
- Administration Method
- Intratumoral injection
- Target Cancers
- Soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple-negative breast cancer, non-small cell lung cancer
- Trial Phase
- Phase I/IIa
- Main Objectives
- Assess safety, tolerability, determine maximum tolerated dose, evaluate antitumor activity
- Combination Therapy
- BT-001 with pembrolizumab
- Key Eligibility Criteria
- Adults 18+, confirmed advanced/metastatic cancer, failed standard treatments, injectable tumor lesion
- Primary Endpoints
- Adverse events, progression-free rate, immune overall response rate
What is BT-001?
BT-001, also known as TG6030, is an innovative medication being studied for the treatment of advanced solid tumors. It is a type of oncolytic virus, which means it's a virus that has been modified to target and kill cancer cells while leaving healthy cells unharmed. BT-001 is administered as a suspension for injection, typically given directly into the tumor (intratumoral injection).
How does BT-001 work?
BT-001 is designed to work in two ways: It directly attacks and kills cancer cells. It stimulates the patient's immune system to fight against the cancer. The medication contains a modified form of the vaccinia virus, which has been engineered to produce two important substances: GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor): This helps activate immune cells to fight the cancer. Anti-CTLA-4 antibody: This is a type of immunotherapy that helps boost the body's immune response against cancer cells. By combining these approaches, BT-001 aims to provide a powerful treatment option for patients with advanced cancers.
What conditions does BT-001 treat?
BT-001 is being studied for the treatment of several types of advanced or metastatic solid tumors, including: Soft tissue sarcoma (STS): A type of cancer that develops in soft tissues like muscles, fat, or blood vessels. Merkel cell carcinoma (MCC): A rare but aggressive type of skin cancer. Melanoma: A serious type of skin cancer that develops in melanocytes (pigment-producing cells). Triple negative breast cancer (TNBC): An aggressive form of breast cancer that lacks certain receptors, making it harder to treat with standard therapies. Non-small cell lung cancer (NSCLC): The most common type of lung cancer. These cancers are considered advanced or metastatic, meaning they have spread beyond their original location.
Clinical Trial Overview
BT-001 is currently being studied in a Phase I/IIa clinical trial. This trial is designed to: Assess the safety and tolerability of BT-001 when given alone and in combination with another immunotherapy drug called pembrolizumab. Determine the best dose of BT-001 to use. Evaluate how effective BT-001 is in treating the targeted cancers. The trial is divided into different parts: Phase I, Part A: Testing BT-001 alone to determine its safety and the right dose to use. Phase I, Part B: Testing BT-001 in combination with pembrolizumab to assess safety and tolerability. Phase II: Evaluating how well BT-001 combined with pembrolizumab works in treating the targeted cancers.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Some key eligibility requirements include: Being 18 years or older Having a confirmed diagnosis of one of the targeted cancers (STS, MCC, melanoma, TNBC, or NSCLC) Having tumors that can be easily injected (such as those on or just under the skin, or in easily accessible lymph nodes) Having tried and not responded to standard treatments, or being unable to tolerate standard treatments Being in relatively good overall health (able to perform daily activities with minimal assistance) There are also several factors that might prevent someone from participating in the trial, such as having certain other medical conditions or having received specific treatments recently.
Potential Benefits and Risks
As with any experimental treatment, BT-001 may offer potential benefits but also carries risks: Potential Benefits: It may help shrink tumors or slow cancer growth in patients who haven't responded to other treatments. It might stimulate the immune system to fight cancer more effectively. It could potentially lead to longer survival or improved quality of life for some patients. Potential Risks: As a virus-based therapy, it might cause flu-like symptoms or other side effects. There's a risk of overstimulating the immune system, which could lead to autoimmune-like side effects. As with any new treatment, there may be unknown risks or side effects that haven't been discovered yet. It's important to discuss these potential benefits and risks thoroughly with a healthcare provider before considering participation in the clinical trial.